We Can Medicines Past Earnings Performance
Past criteria checks 1/6
We Can Medicines's earnings have been declining at an average annual rate of -36.3%, while the Consumer Retailing industry saw earnings growing at 0.4% annually. Revenues have been growing at an average rate of 3.7% per year. We Can Medicines's return on equity is 0.8%, and it has net margins of 0.3%.
Key information
-36.3%
Earnings growth rate
-39.6%
EPS growth rate
| Consumer Retailing Industry Growth | 0.05% |
| Revenue growth rate | 3.7% |
| Return on equity | 0.8% |
| Net Margin | 0.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How We Can Medicines makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 3,228 | 9 | 1,062 | 0 |
| 31 Mar 24 | 3,169 | 6 | 1,030 | 0 |
| 31 Dec 23 | 3,123 | 15 | 990 | 0 |
| 30 Sep 23 | 3,112 | 15 | 998 | 0 |
| 30 Jun 23 | 3,114 | 23 | 1,009 | 0 |
| 31 Mar 23 | 3,212 | 74 | 997 | 0 |
| 31 Dec 22 | 3,303 | 100 | 994 | 0 |
| 30 Sep 22 | 3,206 | 95 | 962 | 0 |
| 30 Jun 22 | 3,134 | 92 | 941 | 0 |
| 31 Mar 22 | 2,964 | 65 | 914 | 0 |
| 31 Dec 21 | 2,794 | 39 | 886 | 0 |
| 31 Dec 20 | 2,667 | 43 | 834 | 0 |
Quality Earnings: 6929 has high quality earnings.
Growing Profit Margin: 6929's current net profit margins (0.3%) are lower than last year (0.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6929's earnings have declined by 36.3% per year over the past 5 years.
Accelerating Growth: 6929's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 6929 had negative earnings growth (-59.5%) over the past year, making it difficult to compare to the Consumer Retailing industry average (7.9%).
Return on Equity
High ROE: 6929's Return on Equity (0.8%) is considered low.